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Background: Temporal lobe epilepsy (TLE) is often characterized pathologically by severe neuronal loss in the
hippocampus. Understanding the mechanisms of neuron death is key to preventing the neurodegeneration associated
with TLE. However, the involvement of neuronal loss to the epileptogenic process has yet to be fully determined.
Recent studies have shown that the activation of NLRP1 can generate a functional caspase-1-containing inflammasome
in vivo to drive the proinflammatory programmed cell death termed ‘pyroptosis’, which has a key role in the pathogenesis
of neurological disorders. To the best of our knowledge, there are no reported studies that performed detailed
identification and validation of NLRP1 inflammasome during the epileptogenic process.
Methods: We first compared expression of NLRP1 and caspase-1 in resected hippocampus from patients with
intractable mesial temporal lobe epilepsy (mTLE) with that of matched control samples. To further examine whether
the activation of NLRP1 inflammasome contributes to neuronal pyroptosis, we employed a nonviral strategy to knock
down the expression of NLRP1 and caspase-1 in the amygdala kindling-induced rat model. Proinflammatory cytokines
levels and hippocampal neuronal loss were evaluated after 6 weeks of treatment in these NLRP1 or caspase-1 deficiency
TLE rats.
Results: Western blotting detected upregulated NLRP1 levels and active caspase-1 in mTLE patients in comparison to
those levels seen in the controls, suggesting a role for this inflammasome in mTLE. Moreover, we employed direct
in vivo infusion of nonviral small interfering RNA to knockdown NLRP1 or caspase-1 in the amygdala kindling-induced rat
model, and discovered that these NLRP1 or caspase-1 silencing rats resulted in significantly reduced neuronal pyroptosis.
Conclusions: Our data suggest that NLRP1/caspase-1 signaling participates in the seizure-induced degenerative process
in humans and in the animal model of TLE and points to the silencing of NLRP1 inflammasome as a promising strategy
for TLE therapy.
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Temporal lobe epilepsy (TLE), a serious, chronic neuro-
logical syndrome in patients presenting refractory seizures,
is characterized pathologically by selective neuronal cell
loss and mossy fiber sprouting in hippocampus and limbic
system. Hippocampal sclerosis (HS) is the most common
lesion found in patients with mTLE. Experimental studies
in animal models of epilepsy and human brain tissue
have revealed a role of progressive damage and consider-
able neuronal death in vulnerable areas such as the
hippocampus of TLE [1,2]. However, the exact molecular
pathogenic mechanisms of neuronal loss are not com-
pletely understood.
Recently, a novel inflammasome signaling pathway
has been uncovered, and a wealth of information link-
ing the activation of inflammasome to neurological dis-
orders pathogenesis has emerged [3]. The NLRP1
inflammasome was first characterized as a member of
the NLRP family, whose activation can generate a func-
tional caspase-1-containing inflammasome in vivo to
drive the proinflammatory programmed cell death
termed ‘pyroptotic death’ [4]. Like apoptosis, pyroptosis
requires the proteolytic activation of specific caspases:
caspase 3 and 7 for apoptosis and caspase-1 for pyroptosis.
In contrast to apoptosis, which is often anti-inflammatory,
pyroptosis is predicted to be proinflammatory due to the
rapid loss of cell membrane integrity and release of
cytosolic contents [5]. In addition, inhibition of the
NLRP1 inflammasome could reduce the innate im-
mune response and ameliorate detrimental conse-
quences inflammation [6,7]. As a critical component of
the inflammasome, NLRP1 appears to be expressed ra-
ther ubiquitously, and high NLRP1 levels were also
found in the brain, in particular in pyramidal neurons
and oligodendrocytes [8]. Although current data re-
garding NLRP1 functions are far scarcer than those
that described for other inflammasome, various studies
have proposed its crucial role in neurological diseases
such as neurodegenerative pathologies, in which in-
flammatory events and neuronal death have a clear
causal role [9]. Thus, we hypothesized that the activa-
tion of NLRP1-inflammasome may have key roles in
the pathogenesis of TLE, in which inflammatory events
and neuronal death contribute powerful pathogenetic
forces [10,11]. To test this hypothesis, we first investigated
whether the expression profiles of the NLRP1 inflamma-
some components, including NLRP1 and caspase-1, are
altered in resected hippocampus from patients with in-
tractable mTLE when compared to matched control sam-
ples. Next, we applied small interfering RNAs (siRNAs) to
knock down NLRP1 and caspase-1 in the brain of amyg-
dala kindling-induced TLE rat model and measured the
NLRP1 component alterations as well as the functional
outcomes.Methods
Temporal lobe epilepsy patients and control group
We collected the hippocampus samples of mTLE pa-
tients. Patients recruited in this study have a diagnosis of
refractory epilepsy according to the definition of phar-
macoresistant epilepsy [12]. The 24-h EEG monitoring
indicated that widespread sharp or spike or slow-waves
originated from unilateral temporal lobe. In addition,
there was ipsilateral hippocampal sclerosis identified by
MRI or low metabolism in ipsilateral mesial temporal
lobe identified by 18F-FDG PET, without other patho-
logical changes. Surgery was determined by a neurologist
and a neurosurgery specialist in consultation. During the
operation, cortical electrode monitoring confirmed that
epilepsy-like waves originated from the inferior temporal
lobe. All patients showed HS, with appreciable neuronal
loss and reactive gliosis in CA1, CA3 and CA4. It was
infeasible to obtain brain tissues of normal hippocampus
cortex, so that normal temporal cortex tissues were used
as negative control. Considering the difficulty in finding
‘real’ controls in human studies, in our experiments we
used ‘healthy’ surgical samples from patients with other
pathologies. Seizure absence was determined by the pa-
tient’s report to the neurologist during the scheduled
visits. Therefore, for comparative purposes, we used six
specimens of nonepileptic tissues from Histologically
normal specimens (control samples) in accordance with
all legal requirements. None of the patients in the con-
trol group had a history of systematic diseases. We also
used autopsy hippocampal tissue as a second control tis-
sue for these studies to avoid problems due to the
localization of specific expression. Autopsy hippocampal
tissues from six patients with no known history of epi-
lepsy and other systematic diseases were used as con-
trols. The average postmortem interval was within 12 h
after death. Routine neuropathological examination of
tissue sections of these control hippocampal samples
showed no pathologic changes. The brain tissues were
separated as needed and immediately preserved in liquid
nitrogen. Clinicopathological data are presented in Table 1,
Additional file 1: Figure S1, and Additional file 2: Figure S2.
The study was approved by the Ethics Committee of
Qingdao Municipal Hospital. Informed consent was ob-
tained from the patients and their legal guardians on
the use of their brain tissues in this research.
Animals
To avoid the interference of estrogen on neuroinflam-
mation [13], only male rats were used in this study.
Adult male Sprague-Dawley rats weighing 260 to 300 g
were obtained from the Experimental Animal Center of
Qingdao University. They were housed in a standard
animal room on a 12 h light/dark cycle with a controlled
temperature and humidity, and given free access to food
Table 1 Clinical data of temporal lobe epilepsy patient group and control groups
(a) Clinical data of temporal lobe epilepsy patient group
Case Sex Age, y Seizure type Duration, y EEG, sp ori MRI/PET HS
1 M 27 CPS, SGS 24 R-T R-HS/R-Ta Wyler III
2 F 24 CPS 22 L-T L-HS/L-Ta Wyler IV
3 F 23 CPS 10 L-T L-HS/ - Wyler III
4 F 33 CPS 26 L-T L-HS/ - Wyler III
5 M 26 CPS 20 R-T R-HS/R-Ta Wyler IV
6 F 26 CPS 10 L-T L-HDA/L-Ta Wyler III
(b) Clinical data of normal temporal cortex tissues control group
Case Sex Age, y Tissue sources
1 M 29 Operative route of benign neoplasm in deep area of brain
2 M 38 Adjacent normal cortex in surgical evacuation of meningioma
3 M 23 Operative route of benign neoplasm in deep area of brain
4 F 37 Adjacent normal cortex in surgical evacuation of BGH
5 F 31 Adjacent normal cortex in surgical evacuation of IH
6 M 33 Operative route of benign neoplasm in deep area of brain
(c) Clinical data of postmortem hippocampal tissue control group
Case Sex Age, y Cause of death
1 M 45 Sudden cardiac death
2 M 24 Car accident
3 F 19 Car accident
4 M 32 Pulmonary artery embolism
5 F 25 Amniotic fluid embolism
6 F 23 Amniotic fluid embolism
BGH, basal ganglia hemorrhage; CPS, complex partial seizure; F, female; HAD, hippocampal degenerative atrophy; HS, hippocampal sclerosis, IH, intracerebral
hematoma; L, left; M, male; R, right; SGS, secondarily generalized seizure; sp ori, spikes origin; T, temporal lobe; y, year.
aIndicates that the positron emission tomography (PET) shows low metabolism.
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cordance with the National Institute of Health Guide for
the Care and Use of Laboratory Animals. Animal care
and sacrifice were conducted according to methods ap-
proved by the Qingdao University Animal Experimenta-
tion Committee. All efforts were made to minimize the
number of animals used and their suffering.
Electrode implantation and temporal lobe epilepsy
induction
Rats were positioned in a stereotaxic apparatus (Stoelting,
USA, www.stoeltingco.com) under deep anesthesia (10%
chloral hydrate, 3.5 mL/kg, i.p.). An electrode was im-
planted into the right basolateral amygdala (AP: -3.0 mm;
L: -4.8 mm; V: -8.8 mm) [14,15]. The electrode was con-
nected to a miniature receptacle, which were fixed to the
skull using dental cement anchored with stainless steel
screws. All rats underwent an identical surgical proced-
ure, which were performed with the use of antiseptic
technique.
After electrode implantation, the rats were allowed
to recover for 2 weeks. Seizures were induced by a20-minute amygdala stimulation (100 ms train of 1 ms,
60 Hz bipolar pulses, 400 μA, every 0.5 s) using a ML1101
electronic stimulator. Electroencephalograms of the right
amygdala were recorded with a digital amplifier (AD
Instrument, Racine, WI, USA). Following electrical stimu-
lation, rats were video-monitored for 8 weeks. The rats
with chronic TLE were identified by occurrence of fre-
quent seizures (at least 2 times IV/V spontaneous seizures
per week) from 1 week after electrical stimulation. Control
rats were handled in the same manner but did not receive
any electrical stimulation. Moreover, our preliminary ex-
periments showed that this amygdala stimulation model is
effective.
siRNA administration in rat brain
We prepared the Entranster in vivo- siRNA mixture
according to the manufacturer’s instructions. Briefly,
50 μg NLRP1 siRNA (Santa Cruz Biotechnology, Inc.,
Dallas, Texas, USA) or caspase-1 siRNA (Santa Cruz Bio-
technology, Inc., Dallas, Texas, USA) or control siRNA
(Santa Cruz Biotechnology, Inc., Dallas, Texas, USA)
was resuspended in 50 μL RNAse-free water to make a
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siRNA solution was mixed with 50 μL Entranster in vivo
transfection reagent (Engreen, Inc., Beijing, China) and
100 μL artificial cerebrospinal fluid (aCSF, composition
in mmol/L: NaCl 130, KCl 2.99, CaCl2 0.98, MgCl2•
6H2O 0.80, NaHCO3 25, Na2HPO4•12H2O 0.039, NaH2
PO4•2H2O 0.46) to get a 200-μL in vivo transfection
mixture. NLRP1 siRNA or caspase-1 siRNA at this dose
was well tolerated, and no signs of neurotoxicity including
hind-limb paralysis, vocalization, food intake, or neuroan-
atomic damage were observed in the preliminary study.
We filled an osmotic pump (Model 2006; ALZET Inc.,
Cupertino, CA, USA) with the in vivo transfection mix-
ture or aCSF alone. Meanwhile, rats were anesthetized
with 10% chloral hydrate (0.3 mL/100 g, intraperitoneal)
and were fixed in a stereotactic frame (Stoelting, USA,
www.stoeltingco.com). A brain-infusion cannula (ALZET
Inc., Cupertino, CA, USA) coupled via vinyl tubing to
the osmotic pump was implanted into the dorsal third
ventricle (AP: -1.8 mm; L: -0 mm; V: -5 mm) of rats with
chronic TLE 8 weeks after electrical stimulation. Mean-
while, the osmotic pump was placed subcutaneously be-
tween the scapulae of rat, and the siRNAs were
continuously infused into the brain at a flow rate of
0.15 μL/hour for 6 weeks by the osmotic pumps. All sur-
gical procedures were ere performed with the use of
antiseptic technique.
Behavioral assessment of seizure
All animals were assessed for amygdala stimulation in-
duced seizures during the first 24 h postsurgery. At the
8th week postsurgery, all animals were re-evaluated for
behavioral progression of seizures 4 h/day for 5 consecu-
tive days to record the spontaneous seizures and scored
according to Racine’s classification [16]: 0, no reaction;
1, stereotypic mounting, eye blinking, and/or mild facial
clonus; 2, head nodding and/or multiple facial clonus; 3,
myoclonic jerks in the forelimbs; 4, clonic convulsions in
the forelimbs with rearing; and 5, generalized clonic con-
vulsions and loss of balance. Numbers and rates of ani-
mals with seizures (at least 2 times IV/V spontaneous
seizures) during the first 24 h post-surgery and on the
6th week post-treatment were recorded.
Brain tissue preparation
Rats were sacrificed under deep anesthesia for the fol-
lowing biochemical assays:
1. For western blot analysis, quantitative real-time
polymerase chain reaction (PCR), and enzyme-
linked immunosorbent assay (ELISA), the rats were
perfused transcardially with 0.9% saline (pH7.4).
Then, the samples were rapidly isolated and placed
in liquid nitrogen until use.2. For cresyl violet staining and TUNEL analysis, rats
were perfused transcardially with 0.9% saline
(pH 7.4), followed by a fixative solution containing
4% paraformaldehyde in PBS (pH 7.4). Then, the
brains were removed and fixed in the same fixative
at 4°C until use.
3. For double immunofluorescence staining, rat brain
was removed without perfusion, embedded in tissue
freezing medium, and immediately frozen at -40°C.
Frozen tissue was stored at -80°C until sectioning.
Western blotting
Tissues samples were digested with RIPA lysis buffer
(50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% Nonidet-
40, 0.5% sodium deoxycholate, 1 mmol/L EDTA, 1 mmol/L
PMSF) with protease inhibitors (pepstatin 1 μg/mL, apro-
tinin 1 μg/mL, leupeptin 1 μg/mL) for 30 min and the
protein concentration was determined using the Bradford
assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Dif-
ferent samples with an equal amount of protein were
separated using 8-12% SDS-polyacrylamide gels and
transferred to PVDF membranes. After blocking with
10% non-fat milk at room temperature, the membranes
were incubated with primary antibodies against NALP1
(1:1000; Novus Biologicals, Inc., Littleton, CO, USA),
NeuN (1:500; Chemicon, www.chemicon.com.br), cleaved
caspase-1 (1:200; Cambridge, UK), cleaved IL-1β (1:500;
Santa Cruz Biotechnology, Inc., Dallas, Texas, USA), and
β-actin (1:1000; Santa Cruz Biotechnology, Inc., Dallas,
Texas, USA) at 4°C overnight. After rinsing, the mem-
branes were appropriately incubated with horseradish per-
oxidase (HRP)-conjugated suitable secondary antibodies
(1:5000; Zhongshan Inc., Beijing, China) for 2 h at room
temperature. Cross-reactivity was visualized using ECL
western blotting detection reagents and analyzed by scan-
ning densitometry using a BioSpectrum Imaging System
(UVP, Upland, CA, USA).
Real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen
Life Technologies, Carlsbad, CA, USA), using the protocol
supplied by the manufacturer. Total RNA was reverse
transcribed to cDNA by the Reverse Transcription System
(Bio-Rad, Hercules, CA, USA). The reaction was per-
formed at 42°C for 50 min, 95°C for 5 min, and 5°C for
5 min, then the cDNA was stored in -20°C. Amplification
was carried out with the Stratagene Mx3000P real-time
PCR system (Stratagene, LaJolla, CA, USA) with a SYBR
Green PCR technology (Takara Bio, Inc., Shiga, Japan). Re-
verse transcription was performed in a final volume of
20 μL containing 2 μL cDNA, 10 μL SYBR Green, 0.4 μL
ROX Reference Dye, 0.4 μL forward and reverse primer
(1 mol/L), and 6.8 μL nuclease-free water. The optimal
conditions were 40 cycles of 95°C for 30 s, 60°C for 32 s,
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the CT values, determined for triplicate reactions of SE
samples and sham samples for each gene. Total RNA
concentrations from each sample were normalized by
quantity of β-actin mRNA, and the target genes’ expres-
sion was evaluated by ratio of the number of target
mRNA to β-actin mRNA. Relative expression of genes
was obtained by the 2-△△CT method. Primers were pur-
chased from Invitrogen as follows (name: forward pri-
mer, reverse primer): nlrp1: 5’-gccctggagacaaagaatcc-3’,
5’-agtgggcatcgtcatgtgt-3’; caspase-1: 5’-aaggtcctgagggcaaa
gag-3’, 5’-gtgttgcagataatgagggc-3’; β-actin: 5’-agggaaatcg
tgcgtgac-3’, 5’-cgctcattgccgatagtg-3’.
ELISA
Levels of secreted IL-1β were measured using commer-
cially available ELISA kit (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instruc-
tions. ELISA was conducted by technicians who were
blinded to the experimental groups. The results are
expressed in pg/mL.
Nissl staining and TUNEL assay
Nissl staining was employed to detect surviving neu-
rons. The brains were embedded in paraffin and cut
into 7-μm sections. Next, the paraffin-embedded sec-
tions were dewaxed and rehydrated according to the
standard protocols. Then, the sections were stained in
1% cresyl violet at 50°C for 5 minutes. After being
rinsed with water, the sections were dehydrated in in-
creasing concentrations of ethanol, mounted on the
slides, and examined with a light microscope. Only the
neurons with violet nucleus and the intact morphology
were counted as surviving neurons. Besides, we used a
cell death detection kit (In Situ Cell Death Detection
Kit, POD; Roche, www.roche.com) for TUNEL assay to
detect neuronal apoptosis. We employed TUNEL assay
via a commercial kit according to the manufacturer in-
structions. Briefly, the paraffin-embedded sections of
samples received deparaffinization and rehydration
treatments, and then were incubated with proteinase-K
for 15 min at room temperature followed by three washes
in PBS. The TUNEL reaction mixture was added and in-
cubated for 60 min at 37°C. Next, sections were washed
with PBS and two drops of peroxidase-streptavidin conju-
gate solution in blocking buffer was applied. Then, the
sections were incubated for 30 min at room temperature,
washed again with PBS and exposed to 0.03% diaminoben-
zidine in 0.01% H2O2. Lastly, sections were counterstained
with Mayer’s hematoxylin, dehydrated, mounted on the
slides and examined with a microscope equipped with a
charge-coupled device camera. We identified the neurons
with deep black nuclei as TUNEL-positive neurons. Cell
counting was performed on five randomly selected non-overlapping fields of per slide. The densities of surviving
neurons or TUNEL-positive neurons in the hippocampus
of the scanned digital images were calculated using
Image-Pro Express software (Media Cybernetics, Silver
Spring, MD, USA). The total cell counts were averaged
from five sections per animal. The survival index was de-
fined as follows: surviving index (%) = 100× (number of
surviving neurons/total number of neurons). Furthermore,
the TUNEL-positive neurons index was defined as follows:
TUNEL-positive neurons index (%) = 100× (TUNEL-posi-
tive neurons/total neurons).
Immunofluorescence staining
For immunofluorescence studies, 20-μm-thick sections
were obtained by cryosectioning at -20°C, mounted on a
glass slide, and incubated at room temperature for
1 hour. Next, the sections were fixed in ice-cold acetone
for 10 minutes and then dried on a heater for 10 minutes
at 40°C. Then, sections were blocked with 5% BSA and
0.1% TritonX-100 for 2 hours. After a single wash with
PBS, sections were incubated overnight at 4°C with a
rabbit polyclonal antibody against NALP1 (1:1000; Novus
Biologicals, Inc., Littleton, CO, USA) combined with a
mouse monoclonal antibody against NeuN (1:200; Chemi-
con, www.chemicon.com.br). Afterward, sections were
washed in PBS and incubated respectively with FITC con-
jugated anti-rabbit IgG (1:200; Santa Cruz Biotechnology,
Inc., Dallas, Texas, USA) and TRITC conjugated anti-
mouse IgG (1:200; Zhongshan Inc., Beijing, China) in a
dark and humidified container for 1 h at 37°C. After that,
the sections were washed with PBS and sealed with a
cover slip. The slides were analyzed with a fluorescence
microscopy (Olympus, Inc, Tokyo, Japan). To ensure the
specificity of the immunoblotting procedure, control ex-
periments were performed in which the corresponding
primary antibody was omitted. Under these conditions, no
signal was observed.
Statistical analysis
Statistical analysis was conducted by SPSS software 17.0
(IBM, Inc., Armonk, NY, USA). After confirming normal
distribution with the skewness and kurtosis statistic test,
an independent sample t-test or one-way ANOVA
followed by a least significant difference (LSD) post hoc
test was used to analyze differences among groups. All
data are expressed as mean ± standard deviation. P <0.05
was considered statistically significant.
Results
NLRP1 inflammasome components were upregulated in
human mesial temporal lobe epilepsy
We first investigated whether the expression of NLRP1
was altered in the brains of individuals with pharmacore-
sistant mTLE. Total proteins were extracted from the
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samples and subjected to western blot analysis. We
found that the NLRP1 levels of TLE patients were sig-
nificantly elevated, while the levels of NeuN were slightly
reduced compared to control samples (Figure 1a, b).
Using double immunofluorescence staining to colocalize
NLRP1 with neuronal marker NeuN, our results further
demonstrated the increased neuronal expression of
NLRP1 in the NeuN-positive neurons of mTLE patients
(Figure 1c). After that, we further investigated the ex-
pression profiles of caspase-1. We found that the expres-
sion of caspase-1, an indicator of pyroptosis, showed a
robust increase in hippocampus of chronic mTLE than
that of controls (Figure 1d). Moreover, we have con-
firmed that the difference between the two controlFigure 1 Increased expression of NLRP1 and caspase-1 in the neuron
and NeuN levels from Case 1 TLE patient and Case 1 ‘healthy control’ indiv
loading control. (b) Levels of NLRP1, NeuN and NLRP1/NeuN were quantifi
deviation. (c) Double immunofluorescent detection of NLRP1 in the NeuN-
individual. (d) The expression level of active caspase-1 (20KD) in Case 3 TLE
western blot assay. Tissue samples from hippocampus of the TLE group an
antibodies and examined under a fluorescence microscope. Scale bars: 20groups was not statistically significant (see Additional
file 3: Figure S3).
Inhibition of NLRP1-attenuated neuron pyroptosis in
temporal lobe epilepsy rats
Next, we investigate the possible mechanism involved in
the neuron pyroptosis with increased NLRP1 level. To-
ward this end, we knocked down brain NLRP1 expres-
sion of TLE rats by using in vivo nonviral RNA
interference methodology [17]. To evaluate the silencing
efficiency of siRNA infusion, the gene expression and
protein level of NLRP1 protein were detected by quanti-
tative real-time PCR and western blotting, respectively.
Compared with control siRNA, NLRP1 siRNA signifi-
cantly reduced the gene expression of NLRP1 in brains of temporal lobe epilepsy (TLE) patient brains. (a) Cerebral NLRP1
idual were detected by western blot analysis. β -actin was used as
ed by densitometric measurement. Values are the mean ± standard
positive neurons of Case 6 TLE patient and Case 6 ‘healthy control’
patient and Case 3 ‘healthy control’ individual was analyzed using the
d control group were immunostained using anti-NLRP1 and anti-NeuN
μm. n = 6 individuals per group.
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changes in gene expression, TLE rats infused with
NLRP1 siRNA showed a dramatic reduction in hippo-
campus NLRP1 protein levels. Incidentally, the NLRP1
levels and gene expression between control-siRNA
treated and No siRNA treated cells do not differ (see
Additional file 4: Figure S4b), excluding an effect of siRNA
transfection on gene expression or the protein level of
NLRP1.Figure 2 NLRP1 inhibition attenuated neuronal pyroptosis in the tem
detected using the TUNEL staining assay in the CA1 region and CA3 region
obtain a better contrast ratio. Neurons with deep black nuclei were identifi
the percentage of TUNEL positive cells among the experimental groups. (c
of rat hippocampus. Neurons with intact morphology were identified as su
of survival neurons among the experimental groups. (e) Cerebral caspase-1
β-actin was used as loading control. (f) The expression level of cleaved IL-1
densitometric measurement. β-actin was used as loading control. All data a
group. *P <0.05, compared with the group of sham rat treated with controThen, we investigate the effects of NLRP1 inhibition on
neuron pyroptosis in TLE rats. The TUNEL staining assay
was firstly used to characterize the pyroptotic effects of
NLRP1. Compared to the control-siRNA group, the in-
creased number of TUNEL-positive cells in the hippocam-
pus of TLE rats could be inhibited by NLRP1 siRNA
treatment (Figure 2a, b). In addition, cresyl violet staining
showed that NLRP1 siRNA led to less obvious neuronal
loss in hippocampus of TLE rat brain (Figure 2c, d). Weporal lobe epilepsy (TLE) rat brain. (a) Neuronal pyroptosis was
of rat hippocampus. Photos were converted to black and white to
ed as TUNEL-positive neurons. Scale bars: 20 μm. (b) Comparison of
) Representative photo of Nissl-staining in CA1 region and CA3 region
rviving neurons. Scale bars: 20 μm. (d) Comparison of the percentage
levels from rat hippocampus were detected by western blot analysis.
β (18KD) was detected by western blot analysis and quantified by
re shown as mean ± standard deviation. Obtained from six rats per
l siRNA.
Table 2 Numbers and rates of animals with seizures
during the first 24 h postsurgery and on the 6th week
post-treatment in experimental groups
(a) Results from sham and temporal lobe epilepsy rats after
6 weeks of treatment with NLRP1 siRNA or control siRNA
Within 24 h post-
stimulation
On the 6th week
post-treatment
Number Rate (%) Number Rate (%)
Sham + Control siRNA 0/18 0 0/18 0
Sham + NLRP1 siRNA 0/18 0 0/18 0
TLE + Control siRNA 18/18 100 14/18 77.8
TLE + NLRP1 siRNA 18/18 100 8/18 44.4a
(b) Results from sham and TLE rats after 6 weeks of treatment with
Caspase-1 siRNA or control siRNA
Sham + Control siRNA 0/18 0 0/18 0
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been known to play a central role in the execution of pyr-
optosis. Western blot analysis was performed to measure
the caspase-1 expression. As indicated in the Figure 2e,
the NLRP1 siRNA treatment could reduce the active
caspase-1 levels in TLE rats. In addition to pyroptosis,
NLRP1 inflammasome is also responsible for caspase-1-
dependent processing of the key pro-inflammatory cyto-
kine IL-1β to an active secreted form [18,19]. In particular,
the activation of IL-1β, which is involved in inflammatory
cycle, is demonstrated to play a key role in TLE pathology
[20]. Therefore, we also inspected the cerebral IL-1β levels
by western blot. Similarly, NLRP1 siRNA treatment also
changes the expression of active IL-1β (Figure 2f) in the
brain of TLE rats.Sham + Caspase-1 siRNA 0/18 0 0/18 0
TLE + Control siRNA 18/18 100 14/18 77.8
TLE + Caspase-1 siRNA 18/18 100b 7/18 38.9b
aP <0.01 (versus TLE + Control siRNA).
bP <0.01 (versus TLE + Control siRNA).Inhibition of NLRP1 reduced seizure frequency and
severity in temporal lobe epilepsy rats
To investigate the effects of NLRP1 siRNA on seizure
frequency and severity in TLE rats, we assessed seizures
of TLE rats during the first 24 h post-surgery and 6th
week post-treatment. Our study demonstrated that sham
rats after 6 weeks of treatment with NLRP1 siRNA or
control siRNA showed no signs of seizure activity during
the first 24 h post-surgery and/or 6th week post-
treatment. In contrast, all rats (100%) in the TLE rats
with control siRNA exhibited high scores of seizures
within the first 24 h post-surgery and 77.8% of them had
seizure activity on the 6th week post-treatment. Mean-
while, TLE rats with NLRP1 siRNA showed lower seiz-
ure activity as compared to the TLE group with control
siRNA within the first 24 h (100%) and only 44.4% of
them had seizure activity on the 6th week post-treatment
and this difference versus TLE rats with control siRNA
was significant for the 6th week post-treatment (Table 2a).Inhibition of Caspase-1 alleviated pyroptosis and seizure
frequency and severity in temporal lobe epilepsy rats
As caspase-1 play a central role in the process of neuron
pyroptosis and IL-1β secretion, we also knocked down
brain caspase-1 in TLE rats by in vivo nonviral RNA
interference methodology for 6 weeks (see Additional
file 1: Figure S1c,d). We found a marked reduction of
TUNEL-positive cell densities in the CA1 and CA3 of
TLE rat hippocampus (Figure 3a, b). Furthermore, cresyl
violet staining showed that NLRP1 siRNA led to less ob-
vious neuronal loss in hippocampus of TLE rat brain
(Figure 3c, d). These results are consistent with the
changes in NLRP1 siRNA-treated TLE rats, supporting
that NLRP1 acts through caspase-1 to exert the ob-
served effects. In addition, the expression of active IL-1β
showed a decrease trend in the TLE rats with caspase-1
siRNA (Figure 3e, f ).As indicated from the Table 2b, sham rats after 6 weeks
of treatment with caspase-1 siRNA or control siRNA
showed no signs of seizure activity during the first 24 h
post-surgery and/or 6th week post-treatment. While
control siRNA-treated TLE rats showed high seizure fre-
quency and severity. In contrast, caspase-1 siRNA treat-
ment could largely reduce seizure frequency and severity
in TLE rats. Only 38.9% of them had seizure activity on
the 6th week post-treatment and this difference versus
TLE rats with control siRNA was significant.
Discussion
Temporal lobe epilepsy (TLE) is often characterized
pathologically by severe neuronal loss in the hippocam-
pus. Understanding the mechanisms of cell death is a
key for preventing the neurodegeneration associated
with TLE. However, the involvement of neuronal death
to the epileptogenic process has yet to be fully determined.
Recent studies shown that the activation of NLRP1 inflam-
masome can generate a functional caspase-1-containing
inflammasome in vivo to drive the proinflammatory pro-
grammed cell death termed ‘pyroptotic death’ [5], which
have key roles in the pathogenesis of neurological disor-
ders [4,21,22]. NLRP1 is also highly expressed in pyram-
idal neurons of the brain [8]. In addition, inflammasome
activation especially the NLRP1 is under current investi-
gation across a broad spectrum of neurological diseases,
including infections, acute sterile brain injury and
chronic neurodegenerative diseases [23]. However, to
the best of our knowledge, there are no reported studies
that performed a detailed identification and validation of
NLRP1 inflammasome during the epileptogenic process.
Figure 3 Inhibition of Caspase-1 alleviated pyroptosis in temporal lobe epilepsy (TLE) rats. Data from TLE rats after 6 weeks of treatment
with caspase-1 siRNA or control siRNA using a mini-osmotic pump. (a) Neuronal pyroptosis was detected using the TUNEL staining assay in the
CA1 and CA3 of rat hippocampus. Neurons with deep black nuclei were identified as TUNEL-positive neurons. Scale bars: 20 μm. (b) Quantitative
analysis of the percentage of TUNEL positive cells among the experimental groups. (c) Representative photo of Nissl-staining in CA1 region and
CA3 region of rat hippocampus. Neurons with intact morphology were identified as surviving neurons. Scale bars: 20 μm. (d) Comparison of the
percentage of survival neurons among the experimental groups. *P <0.05 versus control siRNA treated group. (e) Western blot analysis of cleaved
IL-1β in brain tissues and densitometrical quantification. β-actin was used as loading control. *P <0.05 versus control siRNA treated group. (f) The
presence of IL-1β was measured by ELISA. All data are shown as mean ± standard deviation.
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inflammasome may have key roles in the pathogenesis of
mTLE, in which neuronal death combined with inflamma-
tion contributes powerful pathogenetic forces [24].
Our study was for first time to examine whether the
NLRP1-dependent pyroptosis is a potential mechanism
in TLE pathogenesis in refractory medial temporal lobe
epilepsy patients. We compared expression of NLRP1and caspase-1 in resected hippocampus from patients
with intractable mTLE to matched control samples. The
present study detected upregulated NLRP1 and caspase-
1 levels within mTLE samples than controls. Meanwhile,
the cellular localization of NLRP1 on the neuron in the
mTLE patient brains was demonstrated by the double
immunofluorescence staining, consistent with the find-
ings from the other studies [9]. These elevated NLRP1
Tan et al. Journal of Neuroinflammation  (2015) 12:18 Page 10 of 12inflammasome levels may be induced by potassium (K+)
efflux, which is causative of the generation or spread of
seizure activity in TLE [25,26].
Moreover, we knocked down brain NLRP1 expression
by implanting mini-osmotic pumps for direct infusion of
siRNA to investigate its role on neuronal pyroptosis in
the TLE rat model evoked by amygdala stimulation. This
amygdala stimulation model of chronic TLE in rats pro-
vides a useful tool for studies aimed at understanding
the mechanisms of TLE and exploring the new thera-
peutic strategy for this disease [27,28]. RNA interference
technology has emerged as a potentially superior alter-
native to the traditional approaches for assessing gene
function in adult animals to understand the genes impli-
cated in neuropsychiatric disorders [17,29]. Moreover,
application of the nonviral infusion of siRNA into the
ventricular system could achieve a widespread sequence-
specific gene knockdown in the brain [30]. For the char-
acteristics of rapid, inexpensive, and specific knockdown
of target genes in the whole brain, this method could
provide a useful tool to accelerate the functional investi-
gation of broadly expressed target genes implicated in
neurological disorders. In our study, we found that this
approach effectively downregulates the levels of NLRP1
mRNA and protein in TLE rat brain. Meanwhile, com-
pared to no siRNA treated TLE rat, the treatment with
control siRNA did not alter cerebral NLRP1 mRNA and
protein levels, thus excluding an effect of pump-
mediated infusion on NLRP1 expression levels. For the
first time, we revealed that NLRP1 siRNA treatmentFigure 4 NLRP1 inflammasome contributes to pyroptosis in chronic t
neurons of the brain. The spontaneous seizures may set fire to neuronal NL
activation of NLRP1 inflammasome leads to the caspase-1-mediated pyrop
through several downstream effects in brain. Our current study mainly indi
molecular basis for the spontaneous seizures in TLE process.could significantly reduce TUNEL-positive cell densities
and the active caspase-1 expression levels in TLE rats,
supporting a fundamental role for NLRP1-mediated
pyroptosis in TLE-induced neuronal losses in the
hippocampus.
Meanwhile, we should notice that NLRP1 inflamma-
some is also responsible for caspase-1-dependent pro-
cessing of the key pro-inflammatory cytokine IL-1β to
an active secreted form [18,19]. Pro-inflammatory cyto-
kines, including IL-1β, are known to modulate effects of
neurotoxic neurotransmitters discharged during excita-
tion or inflammation in the central nervous system
(CNS) [31]. Moreover, current studies pointed out that
the inflammatory mechanism contributes powerful
pathogenetic forces in the process of TLE [10]. And recent
studies found that IL-1β was proconvulsant in animal
models of TLE, increasing the time spent in seizures and
reducing the onset time of the first seizure [32]. Hence,
the elevated levels of IL-1β in TLE are believed to serve as
a part of inflammatory cycle that regulates TLE pathology.
Our current research has found that NLRP1 siRNA treat-
ment could change the expression of active IL-1β in the
brain of TLE rat. However, we should notice that there
may be another pathway involved in caspase-1-dependent
processing of the key pro-inflammatory cytokine IL-1β.
Previous studies have pointed out that NLRP3 inflam-
masome also can activate caspase-1 to induce IL-1β se-
cretion [28]. In contrast to the activation of NLRP3,
inflammasome mainly expressed in microglia, which is
essential for the secretion of pro-inflammatory cytokinesemporal lobe epilepsy. High NLRP1 levels were found in pyramidal
RP1 inflammasome via potassium efflux and other channels. Then, the
tosis and secretion of IL-1β, which ultimately induces TLE pathology
cated that the caspase-1-induced neuronal pyroptosis provides a
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expressed in neuron, which is essential for the pyropto-
tic cell death in TLE pathogenesis.
To further investigate whether the NLRP1 acts
through caspase-1 to exert the observed effects of pyrop-
tosis, we also knocked down brain caspase-1 by this
in vivo nonviral RNA interference methodology in TLE
rats. Consistent biochemical results were found between
caspase-1 siRNA and NLRP1 siRNA-treated TLE rats,
supporting that NLRP1 acts through caspase-1 signaling
to exert the effects of pyroptosis. The only difference
was that silencing caspase-1 could markedly reduce ac-
tive IL-1β expression in the TLE rats. As we all know,
caspase-1 is a critical pathway by which inflammasomes
contribute to the downstream effects. Beside the NLRP1,
other inflammasome such as NLRP3 also can activate
caspase-1 to induce IL-1β secretion.
This study also has some limitations. For example, we
cannot rule out the possibility that the 6-week infusion
of NLRP1 siRNA is not enough to cause obvious
changes in TLE-like neuropathology. However, the lim-
ited duration (maximum 6 weeks) of osmotic pumps
suitable for rat prevented us from observing long-term
effects of NLRP1 knockdown. Second, there are limited
ways to stimulate or stably overexpress NLRP1 in brain.
Hence, we cannot provide more direct evidence on the
role of NLRP1 in neuroinflammation and pyroptotic
cell death here. However, it is still worth mentioning
that our findings have important clinical implications.
Although current available interventions can provide
benefits for TLE, none prevents or cures the disease.
Thus, the inhibition of neuronal pyroptosis is a neuro-
protective response and pyroptosis could be restrained
to open exciting new therapeutic perspectives for TLE.
Thus, because inhibition of NLRP1 inflammasome had
several potentially beneficial effects on neuronal pyrop-
tosis and inflammation response in the TLE process,
modulation of NLRP1 inflammasome may be explored
as a promising strategy for the development of TLE
therapy.Conclusions
Our present study first demonstrates that cerebral expres-
sion of NLRP1 was upregulated in refractory medial tem-
poral lobe epilepsy patients. The increase in NLRP1 levels
can activate caspase-1 signaling responsible for neuronal
pyroptosis and inflammation cytokine release (Figure 4).
Using the pump-mediated in vivo infusion of nonviral
siRNA to knock down NLRP1 in the brain of TLE rats,
our study further indicated that inhibition of NLRP1
inflammasome represents a potential clinical benefit of
therapeutic interventions that target inflammasome as-
sembly and activity.Additional files
Additional file 1: Figure S1. Magnetic resonance imaging (MRI)
manifestations of all cases in the temporal lobe epilepsy (TLE) patient
group. (a) Case 1 showed right hippocampal sclerosis. (b) Case 2 showed
left hippocampal sclerosis. (c) Case 5 showed right hippocampal sclerosis.
(d) Case 6 showed left hippocampal degenerative atrophy.
Additional file 2: Figure S2. Positron emission tomography (PET)
manifestations of cases in the temporal lobe epilepsy (TLE) patient group.
(a) Case 1 showed low metabolism in the right temporal lobe. (b) Case 2
showed low metabolism in the left temporal lobe. (c) Case 5 showed low
metabolism in the right temporal lobe. (d) Case 6 showed low metabolism
in the left temporal lobe. Case 3 and Case 4 did not receive PET test.
Additional file 3: Figure S3. Expression of NLRP1 and caspase-1 in the
neurons of two control groups. (a) Cerebral NLRP1 and NeuN levels from
two controls were detected by western blot analysis. β -actin was used as
loading control. Levels of NLRP1, NeuN and NLRP1/NeuN were quantified
by densitometric measurement. Values are the mean ± standard deviation.
(b) The expression level of active caspase-1 (20KD) was analyzed using the
western blot assay. n = 6 individuals per group. Control 1 indicates the
normal temporal cortex tissues; Control 2 indicates postmortem control
hippocampal tissue.
Additional file 4: Figure S4. Short interfering RNA (siRNA) targeting
NLRP1 or caspase-1 effectively downregulated NLRP1 or caspase-1 in
brain of TLE rat model. (a) Messenger RNA levels of NLRP1 in brain of
temporal lobe epilepsy (TLE) rats after a 6-week infusion of artificial
cerebrospinal fluid (aCSF), control siRNA or NLRP1 siRNA. (b) Protein levels
of NLRP1 in the brain of the TLE rats after a 6-week infusion of artificial
cerebrospinal fluid (aCSF), control siRNA, or NLRP1 siRNA. Data are
expressed as a fold change relative to sham group. (c) Messenger RNA
levels of caspase-1 in brain of TLE rats in sham, 6-week infusion of control
siRNA, or caspase-1 siRNA groups. (d) Protein levels of caspase-1 in brain
of TLE rats in sham, 6-week infusion of control siRNA or caspase-1 siRNA
groups. Data are expressed as a fold change relative to TLE rats infused
with control siRNA. Columns represent mean ± standard deviation. n = 6
rats per group.
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